Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer

Fig. 3

The transcription factor NFYA is involved in the transcriptional activation of ALDH2. A Schematic diagram of the ALDH2 promotor region (P1) showing the location of predicted binding sites for the transcription factors, HNF4A and NFYA. The promoter deletions (P2-P3) are shown below. B Dual luciferase reporter assay for the transcriptional activity of three ALDH2 promoter fragments (P1-P3) in NSCLC/PTX cells. **p < 0.01, ***p < 0.001, as compared to the PGL3-Basic group; ###p < 0.001, as compared to the PGL3-P3 group. C The protein expression levels of the NFYA and HNF4A in NSCLC cells and NSCLC/PTX cells. D Luciferase activity elicited by the ALDH2 P1 promotor in NSCLC cells and in NSCLC/PTX cells after overexpression of HNF4A and NFYA. **p < 0.01, ***p < 0.001, as compared to the promotor group. #p < 0.05, ##p < 0.01, as compared to the parental cells group. E Luciferase activity elicited by the NFYA-M1 promoter (the ALDH2 P1 promotor containing the mutated NFYA M1 binding sites, Fig. S4D) in NSCLC/PTX cells after overexpression of NFYA. ***p < 0.001, as compared to the P1 promotor group. ###p < 0.001, as compared to the NFYA overexpression group. F The protein expression levels of NFYA and ALDH2 in NSCLC/PTX cells transfected with NFYA shRNA or scramble. G Statistical analysis of the expression patterns of NFYA and ALDH2 in tissue specimens from 49 NSCLC patients treated with PTX

Back to article page